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A B S T R A C T
Pediatric electrophysiology is a relatively young subspecialty of Pediatric Cardiology, 
but it has experienced rapid progress in the last 2 decades. The revolutionary therapy 
of tachyarrhythmias with catheter ablation transformed the field of pediatric electro-
physiology in a similar or even more dramatic way to that of adult electrophysiology. 
Improvements in technology have made catheter ablation safe in children. Exposure 
to radiation can now be markedly decreased with non-fluoroscopic imaging methods. 
The use of cryothermal energy has made ablation safer in the vicinity of the atrioven-
tricular (AV) node or the coronary arteries. Complex postoperative atrial arrhythmias 
can be managed with advanced electroanatomic mapping technologies. Postoperative 
ventricular tachycardia can be treated with a combination of pharmacologic therapy, 
catheter ablation, surgical methods and implantable defibrillator implantation. Ge-
netically determined arrhythmias can be diagnosed and treated more effectively with 
molecular genetic testing, pharmacologic methods, surgical techniques such as sym-
pathetic denervation and defibrillators. Pediatric electrophysiologists have also adapt-
ed techniques of cardiac resynchronization to children and patients with congenital 
heart disease. Overall, these developments make the present and future of pediatric 
electrophysiology very exciting and promising.
S U P R A V E N T R I C U L A R  T A C H Y C A R D I A
Supraventricular tachycardia (SVT) is the most common sustained arrhythmia in 
children, with an incidence of approximately 1:250. Accessory pathways (APs) account 
for approximately 70% of cases, atrioventricular (AV) node reentry tachycardia for 
20% and atrial ectopic and other tachycardias (e.g. junctional ectopic, atrial flutter, 
etc) for approximately 10% .1
1 .  S V T  A S S o C I A T E D  w I T H  A C C E S S o R Y  PA T H wA Y S
There are several forms of accessory pathways (Table 1). Most common loca-
tions for APs are left lateral and right posteroseptal.2 Most children with an AP have 
otherwise anatomically normal hearts. Congenital heart defects that have been most 
commonly associated with accessory pathways include: Ebstein’s anomaly of the 
tricuspid valve, congenitally corrected transposition of the great arteries, tricuspid 
atresia and heterotaxy syndromes.
Presentation and treatment according to age
Tachycardia due to an AP can present at any age, including fetal life. The special 
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AbbreviAtions
AP = accessory pathway
AV = atrioventricular
AVNRT = atrioventricular node reentry 
tachycardia
CPVT = catecholaminergic polymorphic 
ventricular tachycardia
EAT = ectopic atrial tachycardia
ICD = implantable cardioverter 
defibrillator
LQTS = long QT syndrome
RVOT = right ventricular outflow tract
SVT = supraventricular tachycardia
TOF = tetralogy of Fallot
VT = ventricular tachycardia
WPW = Wolff-Parkinson-White 
(syndrome)
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circumstances of fetal life (lack of continuous monitoring, dif-
ficulty in delivering effective therapy and relative non-compli-
ance of fetal heart) may result in heart failure due to prolonged 
periods of SVT, which may present as hydrops fetalis and 
even fetal death. Treatment of persistent fetal tachycardia is 
usually performed via oral administration of antiarrhythmic 
medications to the mother, but other forms of therapy, such 
as direct umbilical vein delivery can be attempted in resistant 
cases. The most common drugs used in the fetus are digoxin, 
flecainide, amiodarone and sotalol. Intramuscular administra-
tion of drugs such as digoxin may be effective in the hydropic 
fetus, usually in combination with maternal intravenous (IV) 
administration. Delivery of the fetus and direct neonatal 
treatment should be reserved for fetuses near term, to avoid 
complications of prematurity.
Neonatal and infant management of SVT due to APs can 
also be problematic, often requiring multiple medications. For-
tunately, most APs lose conduction during infancy. The natu-
ral history of the Wolff-Parkinson-White (WPW) syndrome 
in infants is marked by spontaneous loss of preexcitation by 
age 1 year in 93% of the patients, but with reappearance of it 
in 31% of children by 8 years of age.3 Thus, it is quite rare for 
an infant to require interventional therapy. In addition, data 
from infant lambs have shown that radiofrequency lesions 
placed in the infantile myocardium can grow with age and 
cause potentially significant structural damage, along with 
the possibility for arrhythmiogenesis due to the irregularity 
of the lesion borders.4 However, a small number of infants 
have been submitted to radiofrequency (RF) ablation and 
there are data from both the Pediatric RF Ablation Registry 
and individual centers on the outcome of these procedures. 
The results are comparable to those in older patients, but only 
when the procedures are performed in experienced centers.5 
In general, the risks of ablation are significantly increased in 
younger patients. A study of the Pediatric Radiofrequency 
Ablation Registry showed that mortality is higher when there 
is underlying heart disease, lower patient weight, greater 
number of radiofrequency energy applications, and left-sided 
procedures.6
Other safety issues
Prospective studies have evaluated the long term outcomes 
of ablation in pediatric patients. No intracardiac thrombosis 
was observed, serious injury to cardiac valves due to RF abla-
tion was very rare, and there was no clear effect of RF ablation 
on cardiac wall motion or on left ventricular function.7 There-
fore RF ablation has become the standard of care in older 
children and adolescents with recurrent symptomatic SVT. 
However, the effects of excessive exposure to radiation are still 
concerning. Fortunately, new developments in technology have 
allowed the performance of these procedures with significant 
reduction, or even complete elimination of radiation. The 
most important electroanatomical mapping systems that have 
been used for this purpose are the CARTO system (Biosense 
Webster, Diamond Bar, CA) and the NavX system (St Jude 
Medical, St Paul, MN) (Figure 1). Several retrospective studies 
have shown the efficacy of both systems in this regard without 
a sacrifice in safety or recurrence rate.8-10
Another recent development in the interventional treat-
ment of SVT in children is cryoablation. The main areas 
where this form of therapy has been found to be beneficial 
are substrates such as the AN nodal reentry tachycardia 
(AVNRT) (see below) and septal APs. There is also evidence 
that cryoenergy is less likely to cause coronary arterial damage 
than radiofrequency energy and therefore it maybe preferable 
when ablating close to the coronary arteries, such as in poster-
oseptal areas. Unfortunately, although the acute success rate 
is similar to RF energy, with no significant complications, the 
recurrence rate is still relatively high and there is a need for 
FIgURE 1. Right atrial and tricuspid valve three- dimensional 
geometry along with electrode-catheters demonstrated using the 
NavX system. Brown spots represent radiofrequency lesions.
TABLE 1. Types of accessory pathways
Atrioventricular non-
decremental
Bidirectional
Unidirectional retrograde only
Unidirectional antegrade only
Retrograde-only decrementally 
conducting (causing PJRT)
Decremental with mostly 
antegrade
conduction (“Mahaim” type)
 
Atrioventricular
Atriofascicular
Nodoventricular
Nodofascicular
Fasciculoventricular (not 
causing tachycardia)
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strategies to improve on this aspect.11,12
Management of asymptomatic WPW syndrome
Sudden death due to rapid conduction of atrial fibrillation 
over the AP is uncommon in pediatric patients because of the 
rare occurrence of this arrhythmia in children. Therefore, until 
recently, there was little impetus in performing ablation proce-
dures in asymptomatic patients. However, recent prospective 
studies in adults and children have shown that asymptomatic 
patients with certain characteristics at electrophysiologic study 
may be at higher risk of dangerous arrhythmias and even sud-
den death. These include the presence of multiple accessory 
pathways, short antegrade refractory period of the pathway 
(<250 ms) and inducibility of tachycardia.13,14 Potentially life-
threatening events occurred in approximately 10% of the study 
population.13 In a prospective randomized study, children with 
high risk characteristics who did not undergo prophylactic ab-
lation had a significantly higher risk of developing potentially 
dangerous arrhythmias and even ventricular fibrillation and 
sudden death. On the other hand, prophylactic ablation did not 
lead to serious complications and eliminated the incidence of 
life-threatening events.15 A survey of Pediatric Electrophysi-
ologists revealed that 83% used invasive electrophysiologic 
studies for risk stratification in asymptomatic patients with 
WPW syndrome. Electrophysiologic findings guided selection 
of patients for RF ablation procedures.16
2 .  AV  N o D E  R E E N T R Y  T A C H Y C A R D I A  ( AV N R T )
This is the second most common form of tachycardia 
in children. Symptoms are often more prominent in these 
patients compared to those with AV reentrant tachycardia 
because the AV valves are closed during atrial contraction, 
and cannon A waves may be seen. Near syncope is also more 
common. AVNRT is unusual in infants less than 2 years of age. 
The natural history of AVNRT in children is largely unknown, 
but episodes are likely to persist into adulthood.
Catheter ablation is indicated when there are frequent 
and/or very symptomatic episodes of tachycardia resistant to 
safe antiarrhythmic therapy or if the patient/family wishes 
to avoid chronic drug therapy. Participation in sports and 
professional choices also may be important factors that lead 
to interventional therapy. For many years RF ablation was 
used for definitive therapy of AVNRT with excellent results. 
However, the incidence of AV block although relatively small 
is not negligible in pediatric series (≈2%), and has led many 
pediatric electrophysiologists to choose cryoablation as a 
safer method. The main advantages of this approach are: a) 
the ability to perform cryomapping at a higher temperature 
(-30oC), the effects of which are completely reversible, before 
deep freezing; b) the stability of the catheter due to ice ball 
formation (cryoadhesion); c) the more gradual lesion forma-
tion, and d) the ability to test AV conduction during freezing. 
The main disadvantages are the smaller size of the lesions and 
the lack of a sign of lesion efficacy such as accelerated junc-
tional rhythm. There have been several series showing similar 
efficacy to RF ablation, but a higher incidence of recurrence. 
There has not been any case of permanent AV block in any of 
the reported cases.17,18
3 .  A T R I A L  E C T o P I C  T A C H Y C A R D I A
This is the third most common cause of tachycardia in 
children and accounts for 5-20% in various series.5 It is not 
uncommon for these patients to present with congestive heart 
failure from tachycardia induced cardiomyopathy which may 
occur in up to 50% of these cases. The mechanism of ectopic 
atrial tachycardia (EAT) is most likely abnormal automatic-
ity. Although the focus of tachycardia is most commonly 
right-sided in adults, equally distributed right and left foci 
are seen in children.
The natural history is one of spontaneous resolution in 
infants and toddlers. This rarely occurs in older children. A 
retrospective study compared the natural history and the re-
sponse to medical therapy in children less than 3 years of age 
to those older than 3 years. The younger patients had a higher 
spontaneous resolution rate (78%) compared with the older 
group (16%) (p < 0.001). Control of AET with antiarrhyth-
mic therapy was achieved in 91% of the younger children but 
only 37% of the older children (p < 0.001). Radiofrequency 
ablation was performed in 35 of the older children, with 
ultimate success in 74%.19 In general, the acute success rate 
has been lower in EAT than in other arrhythmia substrates 
in children. However, a recent study reported 100% success 
rate using electroanatomic mapping, compared to 77% with 
conventional techniques.20
4 .  J U N C T I o N A L  E C T o P I C  T A C H Y C A R D I A
This is the least common form of SVT in children. It oc-
curs mainly in two forms: a) postoperative and b) congenital. 
The postoperative form is usually transient, lasting 1-7 days 
and is usually associated with trauma to the AV node or to the 
His bundle. The rate may be controlled with surface cooling, 
correction of electrolyte imbalance, reduction in the dose of 
IV catecholamines and IV medications. Although various 
drugs have been tried in the past including digoxin, propaf-
enone and procainamide, none has proven very effective, 
except for procainamide which has shown moderate efficacy. 
Amiodarone has become the treatment of choice in cases 
not responding to the usual measures.21 The loading dose is 
5 mg/kg and should be given slowly, over approximately an 
hour and followed by a continuous infusion of 0.4 mg/kg/day. 
Rarely a patient may not respond to all measures, including 
amiodarone and deep hypothermia. In extreme cases, ablation 
of the AV node and implantation of a permanent pacemaker 
has been performed.22
The congenital form is frequently familial, usually inces-
sant, not associated with congenital heart disease, can often 
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spontaneously resolve but only after many months or years 
and can lead to a cardiomyopathy.23 There are reports of 
sudden deaths in patients with junctional ectopic tachycardia 
treated with medications, presumably due to AV block. This 
has prompted a recommendation for back-up pacing in these 
patients, which remains controversial. A recent multicenter 
study on 94 patients reported successful medical treatment 
with amiodarone in 60%. Transcatheter ablation was per-
formed in 44 patients (17 RF ablation, 27 cryo-ablation) with 
equal success rates (82 vs 85%). Pacemaker implantation was 
required in 14%. There were 4 deaths, all in patients younger 
than 6 months of age.24
5 .  A T R I A L  F L U T T E R
This is a rare arrhythmia in children, but it is seen mainly 
on two occasions: a) in young infants or even fetuses, where 
it can be either an isolated phenomenon, or associated with 
Wolff-Parkinson-White syndrome and b) in postoperative 
patients after surgery for congenital heart disease.25 When 
presenting in infancy it is usually transient and all that is 
needed is cardioversion with rapid atrial pacing, usually by the 
esophageal route, or direct current shock. Preventive therapy 
is started if it recurs.
In the postoperative form, the substrate is complex, and 
is related to the atriotomy and patches, natural conduction 
barriers and fibrosis from high pressure and hypertrophy. 
This form is most appropriately called incisional atrial reentry 
tachycardia (IART). It is most commonly seen after surgery 
in the atria, such as the Mustard or Senning operations for 
transposition of the great arteries, the Fontan operation for 
single ventricle and repair of atrial septal defects. It may also 
occur after repair of tetralogy of Fallot and related lesions 
such as truncus arteriosus or double-outlet right ventricle. 
Catheter ablation can achieve a reasonable success rate (be-
tween 80-90%) in most patients except for those with a single 
ventricle, either before or after a Fontan operation.26 However, 
a high recurrence rate (up to 50%) has been reported. In 
patients after surgery for transposition of the great arteries 
or single ventricle, the presence of IART is very detrimental 
and increases the risk of sudden death by 4-fold. Therefore, 
it is mandatory to achieve the best possible control of this ar-
rhythmia. Unfortunately, medical therapy in these patients is 
often unsuccessful and may compromise their hemodynamic 
status. Catheter ablation can be very challenging because of 
the presence of the intraatrial baffle that precludes access 
to the cavo-tricuspid isthmus and to the pulmonary venous 
atrium. Therefore, a retrograde approach (Figure 2), or a 
trans-baffle approach is usually necessary. Despite the techni-
cal difficulties, a reasonable success rate has been achieved 
either with conventional techniques,27 or more recently with 
remote magnetic navigation.28
In patients after an old-style Fontan operation (atrio-pul-
monary or atrio-ventricular connection) atrial arrhythmias 
may be very problematic, because of poor response to an-
tiarrhythmic medications and significant technical difficulties 
with catheter ablation. They often occur in the setting of poor 
hemodynamics and may lead to heart failure, thrombosis 
and death. Because of suboptimal results with catheter abla-
tion and the need to improve hemodynamics, these patients 
are best treated with a revision of the Fontan circuit, which 
involves conversion to an extra-cardiac total cavo-pulmonary 
connection, along with a modified Maze procedure of both the 
right and left atria using cryoablation. Additional arrhythmia 
substrates such as ectopic atrial tachycardias and accessory 
pathways can be managed during these procedures, which 
should be performed in centers with extensive experience.29
V E N T R I C U L A R  A R R H Y T H M I A S
Ventricular tachycardia (VT) in children may occur in 
the setting of a normal heart or in association with structural 
abnormalities (Table 2).
V E N T R I C U L A R  T A C H Y C A R D I A  w I T H  N o R M A L 
H E A R T
Right Ventricular Outflow Tract Tachycardia (RVOT 
VT)
This tachycardia has a characteristic left-bundle branch 
block/inferior axis morphology, may be repetitive or sus-
FIgURE 2. Catheter ablation of atrial flutter in a patient with 
transposition of the great arteries after Senning operation. Ac-
cess to the pulmonary venous atrium is achieved retrogradely 
through the aorta and the right ventricle. The tip of the ablation 
catheter is positioned at the posterolateral part of the cavo-tri-
cuspid isthmus which is bisected by the atrial baffle suture line.
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tained, is not usually inducible by programmed stimulation, 
and has a cycle length that varies with catecholamine levels. 
Its mechanism is likely to be triggered activity. Despite 
the frequent runs of nonsustained VT, most patients are 
asymptomatic. Treatment is indicated when there is reduced 
ventricular function due to high burden of ectopy, or when 
patients are symptomatic. In younger patients who do not 
fulfill these criteria, expectant management is appropriate, 
as spontaneous resolution may occur. A recent multicenter 
study summarized the course and response to therapy in 48 
patients. Most (39/48) were asymptomatic and discovered 
incidentally. Although 26 patients received medical therapy, 
there was no difference in arrhythmia burden compared to 
those who were followed without treatment. Catheter ablation 
was performed in 6 patients and was successful in 4. No patient 
died during follow-up.30
Tachycardias arising from the left ventricle
There are two common types of tachycardia arising from 
the left ventricle. The first has right-bundle branch block/su-
perior axis morphology and arises from the left side of the 
ventricular septum. Its mechanism is most likely reentry 
within the Purkinje network. It has a remarkable sensitivity 
to verapamil. The long term prognosis is usually very good, 
although some patients may develop tachycardia-induced 
cardiomyopathy because of incessant tachycardia. Catheter 
ablation is also very effective, guided by identification of a 
sharp potential preceding ventricular activation, a so-called 
“Purkinje spike”.
A different type of tachycardia may arise from the left 
ventricular (LV) outflow tract or from the aortic sinuses. 
This tachycardia is more similar to RVOT VT in terms of 
mechanism. Successful ablation has been reported in many 
adult and few pediatric series.31
Arrhythmias related to long QT syndrome (LQTS)
The long QT (LQT) syndrome (LQTS) is a heterogeneous 
disorder of various types of cardiac channels. Twelve differ-
ent types have been described. However, the large majority 
of cases are caused by the first 3 types: 1) LQT1 caused by a 
mutation in KCNQ1 gene on chromosome 11, resulting in loss 
of function of the Ik
s
 current; 2) LQT2 caused by a mutation in 
HERG gene on chromosome 7, resulting in loss of function of 
the Ik
r
 current; 3) LQT3 caused by a mutation in SCN5A gene 
on chromosome 3, resulting in a gain of function of the car-
diac sodium channel. Patients having these forms are known 
to be at risk of having episodes of polymorphic ventricular 
tachycardia (VT) (torsade des pointes), but the triggers are 
different: Patients with LQT1 and LQT2 develop syncope 
usually with exertion or loud noise, while LQT3 patients are 
more at risk during sleep or sedentary periods. The main 
methods of therapy are beta-blocking agents, anti-bradycardia 
pacing to prevent pause-induced polymorphic VT, left cardiac 
sympathetic denervation or defibrillator (ICD) implantation. 
Genotype-directed therapy, such as mexiletine for LQT3, or 
potassium supplements for LQT2 may be helpful. Left cardiac 
sympathetic denervation may be performed in the traditional 
way, through a thoracotomy, or less invasively using a vide-
oscopic approach with excellent results.32
A recent study of 128 pediatric patients (ages 8.0 + 5.4 
years) with QTc of 487 + 39 ms assessed the outcome of 
LQTS patients in the era of implantable defibrillators. Beta-
blockers were used in 126 (98%) and pacemaker/implantable 
cardioverter-defibrillator implantation was performed in 27 
(21%) patients, usually because of symptoms despite use of 
beta-blockers. Among them, 22% received an appropriate 
shock, but device-related complications requiring re-interven-
tion occurred in 48%. Device patients had longer QTc intervals 
(p = 0.03) and more symptoms (p < 0.001). No one with an 
isolated KCNQ1 and all patients with an SCN5A mutation 
had device implantation. During the study period, there were 
2 deaths. The authors concluded that in the era of genetic 
testing and device implantation, overall mortality is low with 
treatment. Device therapy, although effective, is not without 
complications and should be reserved for high-risk patients.33 
Recent studies have shown that combination therapy with 
beta-blockers and mexiletine may be effective in especially 
malignant forms of LQT3.34
Catecholaminergic polymorphic VT (CPVT)
This is a rare arrhythmia that may be associated with 
syncope or sudden death during exercise, that may present 
clinically in a similar way to long QT syndrome type 1. The 
QT interval is normal and there is no clue to the diagnosis 
during a baseline 12-lead ECG, other than relative bradycar-
dia. However, the response to exercise is relatively specific 
TABLE 2. Etiologies of ventricular tachycardia in children 
and young adults
 1. Idiopathic ventricular tachycardia from the RVOT or the aor-
tic cusps
 2. Left ventricular tachycardia sensitive to verapamil (fascicular 
VT)
 3. Postoperative VT (tetralogy of Fallot and other congenital 
heart defects)
 4. Cardiomyopathies (dilated, hypertrophic, arrhythmogenic RV 
dysplasia)
 5. Long QT syndrome
 6. Catecholaminergic polymorphic VT
 7. Brugada syndrome
 8. Short QT syndrome
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to this entity, with progressive appearance of polymorphic 
ventricular premature beats, progressing to nonsustained 
VT and sometimes to bidirectional VT (Figure 3). There are 
two types of the disease, an autosomal dominant form due 
to mutations in the RyR2 gene (ryanodine receptors) and an 
autosomal recessive form due to mutations in the CASQ2 gene 
(calsequestrin).35,36 Patients respond to beta-blockers, but not 
to the same degree as with LQT1 and there are patients who 
present with lethal or potentially lethal events while on maxi-
mal b-blockade. There are also reports of improved control 
of ventricular arrhythmias when calcium channel blockers are 
added to beta-blockers.37
The response to treatment with implantable defibrilla-
tors may also be problematic, since the catecholamine surge 
caused by DC shocks may re-induce ventricular tachycardia. 
Inappropriate shocks may also occur due to atrial fibrillation 
which is sometimes observed in these patients. We have also 
seen induction of ventricular fibrillation after DC shocks 
triggered by otherwise hemodynamically stable polymorphic 
ventricular tachycardia (i.e. a form of device-caused proar-
rhythmia). Despite these problems, treatment with ICD can 
be life-saving (Fig 4). There are recent reports that support the 
role of left cardiac sympathetic denervation in the treatment 
of CPVT, in a similar way to LQTS.32,38,39
V E N T R I C U L A R  T A C H Y C A R D I A  w I T H  A N 
A B N o R M A L  H E A R T
In children and young adults the best studied situation is 
the postoperative patient with tetralogy of Fallot (TOF), fol-
lowed by hypertrophic cardiomyopathy and arrhythmogenic 
right ventricular dysplasia, which rarely presents in child-
hood.
V T  I N  P o S T o P E R A T I V E  T o F
Initial studies had estimated that sudden death occurs in 
1-5% of postoperative TOF patients. A more recent prospec-
FIgURE 3. Bidirectional ventricular tachycardia in a patient with catecholaminergic polymorphic VT.
tive population based study of sudden death in patients with 
congenital heart disease has provided a much lower incidence 
of sudden death.40 There was 1 death per 1,118 patient-years, 
with the main diagnoses related to sudden death being aortic 
stenosis, coarctation, transposition of the great arteries and 
tetralogy of Fallot. The incidence of sudden death for these 
diagnoses was 1/454 patients-years. The main risk factors 
known to be associated with VT in postoperative TOF are 
greater length of follow-up, older age at repair (mean 7 years) 
abnormal hemodynamics (elevated systolic or end-diastolic 
RV pressure). An additional risk factor that has been identi-
fied is prolonged QRS duration above 180 ms.41 Initial reports 
suggesting that premature ventricular contraction (PVC) 
suppression decreases the risk of sudden death in patients 
with TOF, have not been confirmed in later studies. Current 
therapy is based on improvement of abnormal hemodynamics 
and treatment of inducible sustained ventricular tachycardia, 
or sustained tachycardia on 24-hour Holter monitor. Treat-
ment with antiarrhythmic drugs has a rather limited and 
mostly adjunctive role in the era of implantable defibrillators 
and radiofrequency ablation. Recent studies have revived the 
importance of electrophysiological studies in the selection 
of candidates for treatment with implantable defibrillators. 
Both monomorphic and polymorphic VT induced during pro-
grammed ventricular stimulation had prognostic significance 
for future development of clinical VT and sudden death.42
The role of implantable defibrillators in the management 
of postoperative VT after TOF repair has been studied in a 
recent retrospective study of 121 patients (median age 33.3 
years). ICDs were implanted for primary prevention in 68 
patients (56.2%) and for secondary prevention in 53 (43.8%), 
defined by clinical sustained ventricular tachyarrhythmia 
or resuscitated sudden death. Overall, 37 patients (30.6%) 
received at least 1 appropriate and effective ICD discharge. 
Annual actuarial rates of appropriate ICD shocks were 7.7% 
and 9.8% in primary and secondary prevention, respectively 
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problems with inappropriate shocks and other complications, 
the implantable defibrillator seems to have a crucial role in the 
management of postoperative VT and sudden death in TOF 
patients.43 Based on a multivariable analysis of factors related 
to appropriate ICD discharges, a scoring system has been cre-
ated (Table 3 ).43 A risk score of <2 identifies patients in very 
low risk (0% annual risk of appropriate shocks), a score of 3-5 
places patients in an intermediate category (3.8% annual rate 
of appropriate shocks), and a score >6 predicts a high risk of 
appropriate shocks (17.5% per year).
Even though catheter ablation has been used for several 
years, the reports referred to isolated cases or small series. A 
recent study of 11 patients presented the results of a systematic 
approach, with ablation of critical isthmuses to prevent all 
potential arrhythmia circuits. The results have been impres-
sive in this small series, with 91% of patients remaining free 
of VT during follow-up for 30 months.44
V T  I N  H Y P E R T R o P H I C  C A R D I o M Y o PA T H Y
Hypertrophic cardiomyopathy (HCM) in children has a 
reported annual mortality rate of 2-6 %. A recent population-
based study including all Australian children who presented 
with primary HCM between 0-10 years of age in a 10-year 
period and followed prospectively for 10 years, revealed a 5- 
and 10-year survival of 83% and 76% respectively. There was 
FIgURE 4A. Dual chamber defibrillator implanted epicardially 
in the same patient is in figure 3. The defibrillator lead has been 
placed behind the left ventricle.
FIgURE 4B. Appropriate ICD therapy in the same patient with CPVT, converting ventricular fibrillation to slower polymorphic VT, 
which eventually terminated spontaneously.
(P=0.11). A higher left ventricular end-diastolic pressure 
(hazard ratio 1.3 per mm Hg, P=0.004) and nonsustained 
ventricular tachycardia (hazard ratio 3.7, P=0.023) independ-
ently predicted appropriate ICD shocks in primary prevention. 
Inappropriate shocks occurred in 5.8% of patients yearly. The 
number of complications was significant at 29.8%. Despite the 
TABLE 3. Risk score for appropriate ICD shocks in primary 
prevention for TOF patients
Risk factor Score
Prior palliative shunt 2
Inducible VT 2
Ventriculotomy 2
LVEDP ≥12 mmHg 3
QRS duration ≥180 msec 1
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only one sudden death, and no patient presented with sudden 
death as the initial manifestation. Two patients presented with 
arrhythmic symptoms. The annual mortality rate was 3.3%, 
but it was 1.5% in patients diagnosed after 1 year of age. The 
main cause of death was heart failure (50%), mostly from 
diastolic dysfunction. A significant proportion of patients had 
genetic syndromes, mainly Noonan’s syndrome. Four patients 
underwent ICD implantations. The indications were aborted 
sudden death, recurrent syncope, easily inducible ventricu-
lar fibrillation during an electrophysiologic study for WPW 
pattern, and a family history of sudden death. None of these 
patients died.45 Ischemia may play a more important role than 
arrhythmias in sudden death of young patients.46 Treatment 
includes high dose beta-blockers, amiodarone and in high 
risk cases ICD implantation. Risk factors for sudden death 
reported for adult patients with HCM include non-sustained 
VT, syncope, malignant family history, extreme hypertrophy 
and abnormal response to exercise. The role of left ventricular 
outflow obstruction is debatable. In a recent study of pediatric 
patients (10.6 + 5.4 years) with HCM, the compound end-point 
of death or heart transplantation occurred in 11% of patients 
over 6.4 years. Only 3 patients died suddenly. Risk factors for 
death included extreme hypertrophy (LV thickness z-score 
>6) and abnormal blood pressure response to exercise.47 The 
occurrence of a resuscitated sudden death episode has been 
considered especially ominous in these patients. A recent study 
by Maron et al including 39 patients who experienced cardiac 
arrest or appropriate ICD shock out of a population of 916 
patients with HCM, reported that the incidence of recurrent 
cardiac arrest was 53%. The remaining patients have not ex-
perienced life-threatening events. Since the follow-up period 
was very long (many patients >10-20 years), the annualized 
incidence of sudden death was 1.4%, similar to that of the 
general HCM population.48
A R R H Y T H M o g E N I C  R I g H T  V E N T R I C U L A R 
D Y S P L A S I A  ( A R V D )
ARVD is a rare genetically determined disease that usu-
ally presents in adolescence or young adulthood, sometimes 
with sudden death as its first manifestation. The diagnosis 
has evolved from postmortem pathology to a clinical and 
laboratory diagnosis during life. The task force criteria are 
very useful in this respect (Table 4).49 Significant progress 
has also been achieved in terms of unraveling the genetic 
TABLE 4. Task force criteria for the diagnosis of ARVD* 49
Category Major Criteria Minor Criteria
Global or regional 
dysfunction and structural 
alterations
(1) Severe dilatation and reduction in the 
RV ejection fraction with no or only mild LV 
impairment
(2) localized RV aneurysms (akinetic-dyskinetic 
areas of diastolic bulging)
(3) Severe segmental dilatation of the RV
(1) Minor global RV dilatation or ejection fraction 
reduction with normal LV
(2) mild segmental dilation of the RV
(3) regional RV hypokinesia
Tissue characterization Fibrofatty replacement of myocardium on 
endomyocardial biopsy
Repolarization 
abnormalities
None Inverted T waves in the right precordial leads beyond 
V1 (patient >12 y, in the absence of a RBBB)
Depolarization or 
conduction abnormalities
Epsilon waves** or localized prolongation (110 ms) 
of the QRS complex in precordial leads (V1, V2, 
or V3)
Late potentials (signal-averaged ECG)
Arrhythmias Sustained LBBB type of VT (as determined with 
electrocardiography, Holter monitoring, or exercise 
testing)
Frequent ventricular extrasystoles with LBBB 
morphology (>1000 per 24 h, as seen with Holter 
monitoring)
Family history Familial disease confirmed at necropsy or surgery (1) Family history of premature sudden death  
(<35 y) caused by suspected RVD or (2) family 
history (clinical diagnosis based on current criteria)
ECG = electrocardiogram; LBBB = left bundle branch block; LV = left ventric-le (-ular); RBBB = right bundle branch block; RV = right ventric-
le(-ular); RVD = right ventricular dysplasia
**Epsilon waves are ventricular postexcitation waves that occur after the QRS complex at the beginning of the ST segment. These waves represent 
delayed depolarization of some parts of the right ventricle.
* To fulfill the appropriate criteria for ARVD, the patient’s condition must meet 2 major criteria, 1 major and 2 minor criteria, or 4 minor criteria.
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background which involves one of several desmosomal pro-
teins. The desmosomes, which are situated in the intercalated 
disc, ensure mechanical coupling between cells and enable 
propagation of electrical impulses. The main components 
of desmosomes consist of the products of three gene super-
families: the desmosomal cadherins, the armadillo family of 
nuclear and junctional proteins, and the plakins.50
Mutations in genes encoding major desmosomal proteins 
(plakoglobin, desmoplakin, plakophilin-2, desmoglein-2, and 
desmocollin-2) have been implicated in the pathogenesis of 
ARVD.51 Mutations in structural components of desmosomes 
found in skin have also been reported resulting in unusual hair 
phenotypes. Naxos disease is an autosomal recessive condi-
tion the clinical features of which comprise arrhythmogenic 
right ventricular cardiomyopathy, woolly hair and palmo-
plantar keratoderma. A homozygous 2 base pair deletion in 
the plakoglobin gene was identified in the above inherited 
disorder.52 Genetic diagnosis is made in approximately 50% 
of suspected cases. The prevalence is between 1/1,000 and 
1/5,000, with 10% of deaths occurring before age 19 and 50% 
before age 35. Electrocardiography (ECG) and signal-aver-
aged ECG (SAECG) have moderate sensitivity for ARVD. 
Endomyocardial biopsy in young individuals with ARVD 
demonstrates fibrosis more frequently than fatty infiltration. 
Newer technologies of magnetic resonance imaging and volt-
age mapping hold promise but require further assessment 
in young individuals suspected to have ARVD.53 A recent 
study attempted a clinical and genetic characterization of 
200 patients. Correlation of ECG, arrhythmic, and cardiac 
magnetic resonance imaging (CMR) findings in the study 
sample revealed 3 patterns of disease expression: (1) classic, 
defined as isolated RV disease (39%) or LV involvement in 
the presence of notable RV enlargement and/or dysfunction; 
(2) left dominant (5%), with prominent LV manifestations in 
the setting of relatively mild right-sided disease; and (3) biven-
tricular (56%), characterized by equal bilateral involvement 
with no apparent predilection for either ventricle. Patients 
with positive genetic testing (n=39) were compared with the 
117 individuals who had screened negative for changes in 
the 5 desmosomal genes. The only significant differences 
were higher LV lesion scores and an increased prevalence 
of left-dominant disease and notable ventricular arrhythmia 
(but not nonsustained VT) in the genotype-positive subset.54 
Some patients respond to medical therapy, but implantation 
of defibrillator should be considered in patients with definite 
diagnosis of ARVD according to task force criteria and those 
with clinical or inducible VT. Patients with arrhythmogenic 
RV dysplasia represent a group with one of the highest rates 
of appropriate ICD shocks (78-85%).55,56
C A R D I A C  R E S Y N C H R o N I z A T I o N
Following the extensive experience of cardiac resynchro-
nization therapy (CRT) with biventricular pacing in adults, 
there has been a rapidly growing utilization of this technology 
in children and patients with congenital heart disease. The 
institutional experience from Boston Children’s Hospital on 
60 patients showed significant benefits from CRT in the major-
ity of patients. Median ejection fraction (EF) increased from 
36% to 42% (P <0.001) and improvement was particularly 
evident in the group with congenital heart disease. Overall, 
an improvement in functional status was observed in 87% 
with sufficient follow-up data.57 Two multicenter studies with 
data on pediatric and congenital heart disease patients have 
been published. In the first study which comprised 103 pa-
tients mostly from North American centers, the largest group 
consisted of patients with congenital heart disease (71%). 
Significant improvements in ejection fraction (12.8 + 12.7%) 
and decrease in QRS (37.7 + 30.7 ms) were seen.58 The second 
multicenter study reporting on 109 patients from European 
centers, also consisted largely of congenital heart disease (87), 
congenital AV block (12) and dilated cardiomyopathy (10). 
The systemic ventricular function improved by 11-14% and the 
functional class by at least 1 grade. The presence of a systemic 
left ventricle was a favorable prognostic factor, whereas dilated 
cardiomyopathy and poor functional class were predictors of 
non-response.59 Patients whose LV dysfunction was related to 
chronic RV pacing responded particularly well to biventricular 
pacing. 59 Finally, CRT has been used in the acute treatment 
of congestive heart failure in the immediate postoperative 
period, especially in patients with single ventricle.60
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